{"id":"oral-zonisamide-therapy","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-20","effect":"Ataxia"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Anorexia"},{"rate":"5-15","effect":"Weight loss"},{"rate":"5-10","effect":"Cognitive impairment"},{"rate":"1-4","effect":"Nephrolithiasis"},{"rate":"1-3","effect":"Hypohidrosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide blocks voltage-gated sodium and T-type calcium channels, reducing repetitive neuronal firing. It also inhibits carbonic anhydrase, which may contribute to its anticonvulsant effects. These combined mechanisms suppress abnormal electrical activity in the brain, making it effective for seizure control.","oneSentence":"Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:54.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial seizures)"},{"name":"Generalized tonic-clonic seizures"}]},"trialDetails":[{"nctId":"NCT04774250","phase":"PHASE2","title":"Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-11-10","conditions":"Hearing Loss, Noise-Induced","enrollment":3},{"nctId":"NCT06967012","phase":"PHASE4","title":"A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-08-01","conditions":"Epilepsies, Partial, Epilepsy, Tonic-Clonic","enrollment":30},{"nctId":"NCT04768569","phase":"PHASE2","title":"Noise-Induced Hearing Loss-Acute Exposure Treatment","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-10-04","conditions":"Hearing Loss, Noise-Induced","enrollment":24},{"nctId":"NCT04182399","phase":"NA","title":"Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-01","conditions":"Parkinson Disease","enrollment":69},{"nctId":"NCT02900352","phase":"PHASE3","title":"Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2016-10","conditions":"Alcohol Use Disorder","enrollment":156},{"nctId":"NCT02368431","phase":"PHASE3","title":"Effectiveness of Zonisamide in Alcohol Dependent Veterans","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2015-03-01","conditions":"Alcohol Use Disorder","enrollment":92},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT01713946","phase":"PHASE3","title":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04-29","conditions":"Tuberous Sclerosis Complex-associated Refractory Seizures","enrollment":366},{"nctId":"NCT00692003","phase":"PHASE3","title":"Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2008-08-01","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT01566370","phase":"PHASE2","title":"Zonisamide for Heavy Drinkers With Bipolar Disorder","status":"TERMINATED","sponsor":"Yale University","startDate":"2012-05","conditions":"Alcohol Use Disorders, Bipolar Disorder","enrollment":3},{"nctId":"NCT00693017","phase":"PHASE3","title":"Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2008-06","conditions":"Epilepsy","enrollment":10},{"nctId":"NCT00862563","phase":"PHASE2","title":"Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2009-05","conditions":"Alcoholism, Alcohol Dependence, Alcohol Abuse","enrollment":85},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT01587339","phase":"","title":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Epilepsy","enrollment":6498},{"nctId":"NCT00401973","phase":"PHASE3","title":"Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-11","conditions":"Schizophrenia, Schizoaffective Disorders","enrollment":199},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral Zonisamide Therapy","genericName":"Oral Zonisamide Therapy","companyName":"Affiliated Hospital of Nantong University","companyId":"affiliated-hospital-of-nantong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition. Used for Epilepsy (adjunctive therapy for partial seizures), Generalized tonic-clonic seizures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}